Drug intelligence / Profile preview

RNDP-003

Development stage: Unknown
Lead developer: Kenai Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

RNDP-003 is an investigational cell therapy developed by Kenai Therapeutics, utilizing induced pluripotent stem cell (iPSC) technology. It is designed as a next-generation allogeneic neuron replacement therapy for neurological diseases, with a primary focus on Parkinson's disease. The drug is currently in the discovery phase and represents an approach to potentially modify disease progression by replacing lost or dysfunctional neurons in the nervous system[1][6]. No detailed mechanism of action or specific molecular targets have been disclosed.

Beyond the preview

Go deeper on RNDP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNDP-003.

Explore the full profile